Fixed combinations of perindopril and indapamide in hypertensive high-risk patients: antihypertensive efficacy

Objective. The aim of the study was to compare the antihypertensive efficacy of fixed combinations of perindopril and indapamide in patients with arterial hypertension (HTN) and high cardiovascular risk. Design and methods. We included 65 patients with 1–2 degree of HTN who had not taken the studied drugs before: either perindopril arginine / indapamide 10 mg + 2,5 mg, n = 35), or indapamide / perindopril erbumine K 2,5 mg + 8 mg, n = 30). Clinical efficacy of antihypertensive therapy was evaluated at three different time points. We assessed objective clinical status, blood biochemistry, office blood pressure (BP), and parameters of daily monitoring of BP (MBP). Results. Perindopril arginine plus indapamide vs indapamide plus perindopril erbumine K after 4 and after 12 weeks shows higher antihypertensive effect regarding office BP and provides significantly better control of the daily BP profile based on the MBP results. Therefore, MBP is required in HTN high-risk patients who take indapamide / perindopril erbuminе K in order to assess the reduction in nighttime BP, independently of achieving target office BP values. 

1. Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA.М.: Медиа Сфера, 2006. 305 с. [Rebrova OYu. Statistical analysis of medical data. Use of the applied program pack od STATISTICA. Мoscow: Media Sphera, 2006. 305 p.].

2. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G et al. On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013; 2013;31(9):1731–68.

3. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В., Шальнова С.А., Яровая Е.Б., Конради А.О. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4–12. [Chazova IE, Zhernakova YuV, Oschepkova EV, Shalnova SA, Yarovaya EB, Konradi AO et al. The abundance of risk factors of cardiovascular diseasesin Russian population of patients with hypertension. Kardiologiia. 2014;10:4– 12. In Russian].

4. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Maragolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125 (13):1635– 1642.

5. Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач. 2009;12:39–42. [Shalnova S, Kukushkin S, Manoshkina E, Timofeeva T. Arterial hypertension and adherence to treatment. Doctor. 2009;12:39–42. In Russian].

6. Клинические рекомендации Министерства здравоохранения Российской Федерации «Диагностика и лечение артериальной гипертонии». Москва, 2013. 64 с. [Clinical recommendations of Ministry of Health of RF “Diagnostics and treatment of arterial hypertension”. Moscow, 2013. 64 p. In Russian].

7. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.

8. Кобалава Ж. Д. Артериальная гипертония: ключи к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 466 с. [Kobalava ZhD. Arterial hypertension: key to diagnostics and treatment. Мoscow: GEOTAR-Media, 2009. 466 p.]

9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual datafor one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.

10. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the night-time blood pressure. Hypertension. 2011;57(1):3–10.

11. Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23(10):645–653.

12. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens. 2007;25(11): 2193–2198.

13. Беленков Ю. Н. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации. Данные ЭПОХА-ХСН (часть 2). Сердечная недостаточность. 2006;7(3):3–7. [Belenkov YuN. Abundance of chronic heart failure in European part of Russian Federation. Data from EPOCHA-CHF study (part 2). J Heart Failure. 2006;7 (3):3–7. In Russian].

14. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B et al. Prognostic signifi cance of blood-pressure variability. Lancet. 2010;375 (9718):895–905.

15. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes TrialBlood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. ASCOT Investigators. Lancet. 2005;366 (9489):895–906.